Open Nav

PanTher Therapeutics, Inc.

  • Laura Indolfi, PanTher Therapeutis, Inc.

Get investors to complete Series A syndicate and partnership to develop second generation products

  • Date:Wednesday, October 17
  • Time:10:00 AM - 10:15 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:PanTher Therapeutics is working to revolutionize the treatment of inoperable, locally advanced solid tumors − studying the direct delivery of proven chemotherapy agents directly onto the tumor for consistent, slow release over time. The company designed its novel delivery method to potentially eliminate the toxic and debilitating side effects that chemo produces when delivered systemically through traditional IV/oral administration. Its first potential indication is pancreatic cancer, a particularly lethal disease where excruciating symptoms arise from primary mass invading nearby vital organs. By changing the route of administration to target just the tumor, PanTher is designed to increase amount of drug reaching the intended destination with the aim to enhance therapeutic efficacy. Eliminating adverse outcomes may also lower healthcare costs. PanTher is completing pre-clinical studies prior to initiate human trials and exploring opportunities for partnerships to expand its pipeline.
  • Company
  • Company HQ City:Cambridge
  • Company HQ Country:United States
  • Company HQ State:Massachusetts       
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :PTM-101 - biodegradable implant for localized delivery of chemotherapy
  • Development Phase of Primary Product:Pre-Clinical
  • Total Amount Raised to Date, In All Rounds:$1.5M
Laura Indolfi
PanTher Therapeutis, Inc.